N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence
Purpose To review available evidence on the effectiveness of N -acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury. Method Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews....
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2013-07, Vol.69 (7), p.1375-1390 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1390 |
|---|---|
| container_issue | 7 |
| container_start_page | 1375 |
| container_title | European journal of clinical pharmacology |
| container_volume | 69 |
| creator | Hosseinjani, Hesamoddin Moghaddas, Azadeh Khalili, Hossein |
| description | Purpose
To review available evidence on the effectiveness of
N
-acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury.
Method
Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews. A total of 26 relevant experimental studies up to the date of publication were included in the review.
Results
Available evidence shows that NAC has the potential to exert significant protective or ameliorative effects against drug-induced kidney injury in experimental models. The possible suggested renoprotective mechanisms of NAC in different experimental settings were acting as an antioxidant by restoring the pool of intracellular reduced glutathione, scavenging of free radicals, and/or interacting with reactive oxygen species.
Conclusion
Whether the administration of NAC could be an effective protective clinical strategy to prevent drug-induced kidney injury or not is a question that remains to be answered in future clinical trials. |
| doi_str_mv | 10.1007/s00228-013-1494-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1365840712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2991172661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-69a0796c2e5463c1f5f5674e572651f84cc5d3d6fd6d6caf3d3eb05184f106be3</originalsourceid><addsrcrecordid>eNp1kE1vEzEQhi0EoqHwA7ggS4ij6Xj9sbvcUFU-pKpc2vPKscfFIbGD7a20R_45jhIKF-SDJc8z73geQl5zeM8B-osC0HUDAy4Yl6NkwxOy4lJ0jIPkT8kKQHCmxx7OyItSNgBcjSCek7NOKBi01ivy64YZi3XZ2qVUDBGpT5nW70j3GR8w1pAiTZ7GFJlNsWZTKt2hC4aa-1ZmIbrZoqM_gou40BA3c14-UJ_T7hBhtyEGa7bUmWpoTfTxAR-Cw2jxJXnmzbbgq9N9Tu4-Xd1efmHX3z5_vfx4zayErrY1DPSjth0qqYXlXnmle4mq77TifpDWKiec9k47bY0XTuAaFB-k56DXKM7J22PuPqefM5Y6bdKcYxs5caHVIKHnXaP4kbI5lZLRT_scdiYvE4fpIH06Sp-a9OkgfRpaz5tT8rxuah47_lhuwLsTYEpb3WcTbSh_uV71YzuN645caaV4j_mfL_53-m8F85tE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1365840712</pqid></control><display><type>article</type><title>N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Hosseinjani, Hesamoddin ; Moghaddas, Azadeh ; Khalili, Hossein</creator><creatorcontrib>Hosseinjani, Hesamoddin ; Moghaddas, Azadeh ; Khalili, Hossein</creatorcontrib><description>Purpose
To review available evidence on the effectiveness of
N
-acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury.
Method
Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews. A total of 26 relevant experimental studies up to the date of publication were included in the review.
Results
Available evidence shows that NAC has the potential to exert significant protective or ameliorative effects against drug-induced kidney injury in experimental models. The possible suggested renoprotective mechanisms of NAC in different experimental settings were acting as an antioxidant by restoring the pool of intracellular reduced glutathione, scavenging of free radicals, and/or interacting with reactive oxygen species.
Conclusion
Whether the administration of NAC could be an effective protective clinical strategy to prevent drug-induced kidney injury or not is a question that remains to be answered in future clinical trials.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-013-1494-8</identifier><identifier>PMID: 23508666</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Acetylcysteine - therapeutic use ; Animals ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - antagonists & inhibitors ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - antagonists & inhibitors ; Antioxidants - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Evidence-Based Medicine ; Humans ; Kidney - drug effects ; Kidneys ; Medical sciences ; Pharmacology ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Preventive medicine ; Protective Agents - therapeutic use ; Renal Insufficiency - chemically induced ; Renal Insufficiency - prevention & control ; Review Article ; Toxicity</subject><ispartof>European journal of clinical pharmacology, 2013-07, Vol.69 (7), p.1375-1390</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-69a0796c2e5463c1f5f5674e572651f84cc5d3d6fd6d6caf3d3eb05184f106be3</citedby><cites>FETCH-LOGICAL-c402t-69a0796c2e5463c1f5f5674e572651f84cc5d3d6fd6d6caf3d3eb05184f106be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-013-1494-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-013-1494-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27579797$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23508666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hosseinjani, Hesamoddin</creatorcontrib><creatorcontrib>Moghaddas, Azadeh</creatorcontrib><creatorcontrib>Khalili, Hossein</creatorcontrib><title>N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose
To review available evidence on the effectiveness of
N
-acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury.
Method
Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews. A total of 26 relevant experimental studies up to the date of publication were included in the review.
Results
Available evidence shows that NAC has the potential to exert significant protective or ameliorative effects against drug-induced kidney injury in experimental models. The possible suggested renoprotective mechanisms of NAC in different experimental settings were acting as an antioxidant by restoring the pool of intracellular reduced glutathione, scavenging of free radicals, and/or interacting with reactive oxygen species.
Conclusion
Whether the administration of NAC could be an effective protective clinical strategy to prevent drug-induced kidney injury or not is a question that remains to be answered in future clinical trials.</description><subject>Acetylcysteine - therapeutic use</subject><subject>Animals</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - antagonists & inhibitors</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - antagonists & inhibitors</subject><subject>Antioxidants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Kidney - drug effects</subject><subject>Kidneys</subject><subject>Medical sciences</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Preventive medicine</subject><subject>Protective Agents - therapeutic use</subject><subject>Renal Insufficiency - chemically induced</subject><subject>Renal Insufficiency - prevention & control</subject><subject>Review Article</subject><subject>Toxicity</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1vEzEQhi0EoqHwA7ggS4ij6Xj9sbvcUFU-pKpc2vPKscfFIbGD7a20R_45jhIKF-SDJc8z73geQl5zeM8B-osC0HUDAy4Yl6NkwxOy4lJ0jIPkT8kKQHCmxx7OyItSNgBcjSCek7NOKBi01ivy64YZi3XZ2qVUDBGpT5nW70j3GR8w1pAiTZ7GFJlNsWZTKt2hC4aa-1ZmIbrZoqM_gou40BA3c14-UJ_T7hBhtyEGa7bUmWpoTfTxAR-Cw2jxJXnmzbbgq9N9Tu4-Xd1efmHX3z5_vfx4zayErrY1DPSjth0qqYXlXnmle4mq77TifpDWKiec9k47bY0XTuAaFB-k56DXKM7J22PuPqefM5Y6bdKcYxs5caHVIKHnXaP4kbI5lZLRT_scdiYvE4fpIH06Sp-a9OkgfRpaz5tT8rxuah47_lhuwLsTYEpb3WcTbSh_uV71YzuN645caaV4j_mfL_53-m8F85tE</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Hosseinjani, Hesamoddin</creator><creator>Moghaddas, Azadeh</creator><creator>Khalili, Hossein</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20130701</creationdate><title>N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence</title><author>Hosseinjani, Hesamoddin ; Moghaddas, Azadeh ; Khalili, Hossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-69a0796c2e5463c1f5f5674e572651f84cc5d3d6fd6d6caf3d3eb05184f106be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylcysteine - therapeutic use</topic><topic>Animals</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - antagonists & inhibitors</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - antagonists & inhibitors</topic><topic>Antioxidants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Kidney - drug effects</topic><topic>Kidneys</topic><topic>Medical sciences</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Preventive medicine</topic><topic>Protective Agents - therapeutic use</topic><topic>Renal Insufficiency - chemically induced</topic><topic>Renal Insufficiency - prevention & control</topic><topic>Review Article</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosseinjani, Hesamoddin</creatorcontrib><creatorcontrib>Moghaddas, Azadeh</creatorcontrib><creatorcontrib>Khalili, Hossein</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosseinjani, Hesamoddin</au><au>Moghaddas, Azadeh</au><au>Khalili, Hossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>69</volume><issue>7</issue><spage>1375</spage><epage>1390</epage><pages>1375-1390</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose
To review available evidence on the effectiveness of
N
-acetylcysteine (NAC) as a prophylactic agent in the prevention of non-contrast media agent-induced kidney injury.
Method
Data were collected by searching Scopus, PubMed, Medline, Science direct and Cochrane database systematic reviews. A total of 26 relevant experimental studies up to the date of publication were included in the review.
Results
Available evidence shows that NAC has the potential to exert significant protective or ameliorative effects against drug-induced kidney injury in experimental models. The possible suggested renoprotective mechanisms of NAC in different experimental settings were acting as an antioxidant by restoring the pool of intracellular reduced glutathione, scavenging of free radicals, and/or interacting with reactive oxygen species.
Conclusion
Whether the administration of NAC could be an effective protective clinical strategy to prevent drug-induced kidney injury or not is a question that remains to be answered in future clinical trials.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23508666</pmid><doi>10.1007/s00228-013-1494-8</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2013-07, Vol.69 (7), p.1375-1390 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_journals_1365840712 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Acetylcysteine - therapeutic use Animals Anti-Infective Agents - adverse effects Anti-Infective Agents - antagonists & inhibitors Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors Antineoplastic Agents - adverse effects Antineoplastic Agents - antagonists & inhibitors Antioxidants - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Evidence-Based Medicine Humans Kidney - drug effects Kidneys Medical sciences Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Preventive medicine Protective Agents - therapeutic use Renal Insufficiency - chemically induced Renal Insufficiency - prevention & control Review Article Toxicity |
| title | N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A43%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-acetylcysteine%20for%20the%20prevention%20of%20non-contrast%20media%20agent-induced%20kidney%20injury:%20from%20preclinical%20data%20to%20clinical%20evidence&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Hosseinjani,%20Hesamoddin&rft.date=2013-07-01&rft.volume=69&rft.issue=7&rft.spage=1375&rft.epage=1390&rft.pages=1375-1390&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-013-1494-8&rft_dat=%3Cproquest_cross%3E2991172661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1365840712&rft_id=info:pmid/23508666&rfr_iscdi=true |